Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

Published:2011-08-24 Issue:1 Volume:53 Page:110-117
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Al-Ali Haifa K.,Jaekel Nadja,Junghanss Christian,Maschmeyer Georg,Krahl Rainer,Cross Michael,Hoppe Gisa,Niederwieser Dietger

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.606382

Reference33 articles.

1. Prognostic factors in acute myeloid leukaemia

2. The Difficult Problem of Acute Myeloid Leukemia in the Older Adult

3. Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

4. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.

5. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML;Leukemia Research;2024-08

2. Safety, Efficacy, and Predictive Factors of Venetoclax-Based Regimens in Elderly Acute Myeloid Leukemia Patients: A Meta-Analysis;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. Ven the dose matters: Venetoclax dosing in the frontline treatment of AML;Blood Reviews;2024-08

4. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children;Clinical Epigenetics;2024-05-09

5. Low‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia;Oncology Letters;2024-03-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3